# HPV FOCAL study: human papillomavirus testing for cervical cancer screening

Submission date	Recruitment status	[X] Prospectively registered		
20/04/2007	No longer recruiting	Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/04/2007	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
11/10/2021	Cancer			

#### Plain English summary of protocol

Background and study aims

Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina). Almost all cases of cervical cancer are caused by the human papilloma virus (HPV). The aim of this study is to evaluate primary HPV testing for cervical cancer screening in an organized program setting in Canada.

#### Who can participate?

Women aged 25 to 65 attending a collaborating BC healthcare provider for regular cervical cancer screening (pap tests)

#### What does the study involve?

Participants have a cervical sample obtained from their usual health care provider. Upon receipt at the lab, the cervical sample (liquid based collection device) is randomly allocated to either HPV testing or cytology testing (Pap test, to detect abnormal cells that may develop into cancer if left untreated). Participants with negative results are recalled at either 2 years or 4 years after their first sample. Participants with positive results are managed according to a specific study protocol. The incidence of cervical cancer is measured after four years.

What are the possible benefits and risks of participating?

Participants have access to close monitoring and enhanced screening. Some participants may be recommended for colposcopies they would not have received outside of the study setting.

Where is the study run from? BC Cancer (Canada)

When is the study starting and how long is it expected to run for? August 2007 to December 2014

Who is funding the study?
Canadian Institutes of Health Research (Canada)

Who is the main contact?

1. Dr Andrew J Coldman (scientific) acoldman@bccancer.bc.ca

2. Ms Laurie Smith (public) lsmith3@bccancer.bc.ca

# **Contact information**

#### Type(s)

Scientific

#### Contact name

Dr Andrew J Coldman

#### Contact details

BC Cancer 711-750 West Broadway Vancouver Canada V5Z 1G1 +1 (0)604 877 6000 x4829 acoldman@bccancer.bc.ca

#### Type(s)

Public

#### Contact name

Ms Laurie Smith

#### Contact details

BC Cancer 711-750 West Broadway Vancouver Canada V5Z 1H6 +1 (0)604 877 6098 ext. 4829 lsmith3@bccancer.bc.ca

# Additional identifiers

# ClinicalTrials.gov (NCT)

NCT00461760

#### Protocol serial number

MCT-82072

# Study information

Scientific Title

A multicentre randomised controlled parallel group evaluation of Human PapillomaVirus testing for cervical cancer screening

#### Acronym

**HPV FOCAL** 

#### **Study objectives**

- 1. Establish efficacy of human papillomavirus (HPV) testing as stand alone screening test with cytology triage of HPV positive women
- 2. Establish an appropriate screening interval for HPV negative women
- 3. Determine cost-effectiveness of HPV testing as a primary screening test

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Research Ethics Board of the University of British Columbia-British Columbia Cancer Agency, 03 /04/2007, ref: H06-04032

#### Study design

Multicentre three-arm randomised parallel-trial on diagnostic strategy with data analyst blinding

#### Primary study design

Interventional

#### Study type(s)

Diagnostic

#### Health condition(s) or problem(s) studied

Human papillomavirus (HPV), cervical cancer

#### **Interventions**

1. HPV testing two-year safety check arm - liquid based cytology (LBC) sample tested only for HPV:

Those who are HPV negative will be screened again in two years for their exit screen, only with cytology so the results correlate with women in the control arm. Those who are HPV positive on the initial screening test will be managed the same way as HPV positive women in the four-year intervention arm.

2. HPV testing four-year intervention arm - 24. a.2.d. experimental intervention dose, duration, etc - LBC sample will only be tested for HPV:

HPV negatives will have their exit screen at four years (or earlier if deemed by Data Safety and Monitoring Committee) when they will be screened with HPV and cytology testing and those positive on either test referred for Colposcopy. HPV positive on their initial screen will have the residual of that specimen analysed with cytology.

#### Initial information at time of registration:

a. If cytology negative they will be recalled at six month intervals for HPV/cytology testing and referred for colposcopy if greater than or equal to abnormal squamous cells of undetermined significance (ASCUS-US) at any recall or persistently HPV positive after three recalls

#### Amended as of 12/03/2018:

2. a: If cytology negative they will be recalled at twelve month intervals for HPV/cytology testing and referred for colposcopy if greater than or equal to abnormal squamous cells of undetermined significance (ASCUS-US) at any recall or persistently HPV positive

b. If cytology is greater than or equal to ASCUS-US they will be immediately referred for colposcopy and managed according to those results.

#### Initial information at time of registration:

3. Control arm - Conventional cytology with liquid based cytology - 24. b.1.cd. control intervention dose, duration, etc:

Liquid based cytology sample processed for cytology and followed according to existing provincial guidelines. Recalled again at two years for their second routine screen and at four years for their exit screen where they will be screened with cytology and HPV testing.

#### Amended as of 19/03/2009:

3. Control arm - Conventional cytology with liquid based cytology -

On the basis of this result women will be managed as follows:

Within normal limits (negative results): Recalled for their next routine screen at 2 years, where the sample will undergo cytology testing. If negative again at the 2 year screen, recalled, for the exit screen at 4 years. At the 4 year exit screen, the sample obtained will undergo both HPV and cytology testing with those positive on either test being referred for colposcopy and then treated based on the colposcopy results.

ASC-H or greater than LSIL (12/03/2018: changed to greater than or equal to LSIL): (at recruitment visit or at the 2 year screen) will receive immediate colposcopy and treated based on the colposcopy results.

ASC-US: (at recruitment visit or at the 2 year screen) the residual of the specimen collected will undergo HPV testing. Follow-up based on the result of the HPV test:

a. HPV-positive: referred for immediate colposcopy and treated based on the colposcopy results b. HPV-negative: recalled for repeat cytology testing in 12 months. If greater than or equal to ASC-US, referred for colposcopy and treated based on the colposcopy results. If cytology negative they will be returned to the routine screening pool for this arm.

#### Added 10/01/2011:

Recruitment to the safety arm will terminate 31/12/2010 and from that point forward, women will be randomized 1:1 into the cytology or intervention arms only. A total of ~28,000 women (11,000 each in the Control and Intervention arms respectively, and ~6,000 in the Safety arm) will be enrolled in the FOCAL trial.

# Added 12/03/2018:

(Ethics board approved amendment 2011): After review and modifications to safety analysis plan, the overall sample size calculation was revised. Revising this calculation and using an 80% power threshold for the comparisons originally included, indicates that a sample size of ~9,140 subjects in the cytology and intervention arms is appropriate.

#### Intervention Type

Other

#### Phase

**Not Specified** 

# Primary outcome(s)

Current primary outcome measures as of 12/03/2018:

1. CIN grade 3 or greater (CIN3+) detected over the four years post recruitment in the control and intervention arms evaluated and compared as a surrogate marker for estimating reductions in incidence of cervical cancer, measured at four years

Previous primary outcome measures:

- 1. Histologically confirmed cervical intraepithelial neoplasia (CIN) greater than or equal to grade two detected at two years in both the control and safety-check arms
- 2. CIN grade three (CIN3) or greater detected over the four years post recruitment in the control and intervention arms evaluated and compared as a surrogate marker for estimating reductions in incidence of cervical cancer, measured at four years
- 3. Detection of histologically confirmed greater than or equal to CIN3 in the participants allocated to six month re-testing, measured at two years
- 4. Total estimated cost per woman screened and total estimated cost per quality-adjusted lifeyear gained for each technology, measured at four years

#### Key secondary outcome(s))

Current secondary outcome measures:

- 1. Histologically confirmed cervical intraepithelial neoplasia grade 2 or greater (CIN2+) two detected at two years in both the control and safety-check arms
- 2. CIN2+ detected in the control and intervention arms over the four years post recruitment
- 3. Clearance of HPV infection in women who are HPV positive at recruitment, measured at two and four years
- 4. Detection of histologically confirmed greater than or equal to CIN3 in the participants allocated to 12 month re-testing, measured at two years
- 5. Evaluation of the impact of primary HPV testing on colposcopy services through evaluation of colposcopy referral rates in each arm through the trial follow-up period
- 6. Total estimated cost per woman screened and total estimated cost per quality-adjusted lifeyear gained for each technology, measured at four years

Previous secondary outcome measures:

Clearance of HPV infection in women who are HPV positive at recruitment, measured at two and four years

# Completion date

31/12/2014

# **Eligibility**

#### Key inclusion criteria

Current information as of 04/11/2008:

- 1. Women aged 25 to 65 years
- 2. Registered with MSP
- 3. Attending a collaborating BC healthcare provider for regular cervical cancer screening (paptests)

Initial information at time of registration:

- 1. Women aged 25 to 65 years
- 2. British Columbia residents
- 3. Eligible for routine cervical screening

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Sex

**Female** 

#### Key exclusion criteria

Current information as of 01/12/2009 (effective 25/11/2009):

- 1. Pap smear less than one year ago
- 2. Pregnant (at time of initial sample)
- 3. History of moderate to severe cervical intraepithelial neoplasia (greater than CIN2) requiring treatment less than 5 years ago
- 4. History of invasive cervical cancer at any time
- 5. Complete hysterectomy with cervix removal
- 6. Human immunodeficiency virus (HIV) positive or receiving immunosuppressive treatments
- 7. Unable or unwilling to sign the Information and Consent form

#### Information as of 04/11/2008:

- 1. Pap smear less than one year ago
- 2. Pregnant
- 3. History of moderate to severe cervical intraepithelial neoplasia (greater than CIN2) requiring treatment less than 5 years ago
- 4. History of cervical cancer at any time
- 5. Complete hysterectomy with cervix removal
- 6. Human immunodeficiency virus (HIV) positive or receiving immunosuppressive treatments
- 7. Received HPV vaccination
- 8. Unable or unwilling to sign the Information and Consent form

#### Initial information at time of registration:

- 1. Pregnant
- 2. History of cervical cancer
- 3. Hysterectomy
- 4. Human immunodeficiency virus (HIV) positive
- 5. Unable to give informed consent

#### Date of first enrolment

01/01/2008

#### Date of final enrolment

30/05/2012

# Locations

#### Countries of recruitment

# Study participating centre BC Cancer

750 West Broadway Vancouver

Canada

V5Z 4G8

# Study participating centre Cervical Cancer Screening Laboratory

686 West Broadway

Vancouver

Canada

\_

# Study participating centre BC Centre for Disease Control Public Health Laboratory

655 West 12th Ave Vancouver

Canada

V5Z 4R4

## Study participating centre BC Cancer Pathology Laboratory

600 West 10th Avenue

Vancouver

Canada

-

# Study participating centre Royal Jubilee Pathology Laboratory

1952 Bay St.

Victoria

Canada

\_

# Sponsor information

#### Organisation

Provincial Health Services Authority (Canada)

#### **ROR**

https://ror.org/01jvd8304

# Funder(s)

# Funder type

Research organisation

#### **Funder Name**

Canadian Institutes of Health Research (ref: MCT-82072)

#### Alternative Name(s)

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR\_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

#### Funding Body Type

Government organisation

#### Funding Body Subtype

National government

#### Location

Canada

# **Results and Publications**

#### Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

# IPD sharing plan summary

Data sharing statement to be made available at a later date

#### **Study outputs**

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	preliminary results	24/03/2010	Yes	No
Results article	results	16/12/2015	Yes	No
Results article	results	03/07/2018	Yes	No

Results article		07/10/2021	11/10/2021 Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025 No	Yes
Study website	Study website	11/11/2025	11/11/2025 No	Yes